FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2512856880> ?p ?o ?g. }

• W2512856880 endingPage "2434" @default.
• W2512856880 startingPage "2426" @default.
• W2512856880 abstract "Recently, incretin-related agents have been reported to attenuate insulin resistance in animal models, although the underlying mechanisms remain unclear. In this study, we investigated whether anagliptin, the dipeptidyl peptidase 4 (DPP-4) inhibitor, attenuates skeletal muscle insulin resistance through endothelial nitric oxide synthase (eNOS) activation in the endothelial cells. We used endothelium-specific Irs2-knockout (ETIrs2KO) mice, which show skeletal muscle insulin resistance resulting from a reduction of insulin-induced skeletal muscle capillary recruitment as a consequence of impaired eNOS activation.In vivo, 8-week-old male ETIrs2KO mice were fed regular chow with or without 0.3% (wt/wt) DPP-4 inhibitor for 8 weeks to assess capillary recruitment and glucose uptake by the skeletal muscle. In vitro, human coronary arterial endothelial cells (HCAECs) were used to explore the effect of glucagon-like peptide 1 (GLP-1) on eNOS activity.Treatment with anagliptin ameliorated the impaired insulin-induced increase in capillary blood volume, interstitial insulin concentration and skeletal muscle glucose uptake in ETIrs2KO mice. This improvement in insulin-induced glucose uptake was almost completely abrogated by the GLP-1 receptor (GLP-1R) antagonist exendin-(9-39). Moreover, the increase in capillary blood volume with anagliptin treatment was also completely inhibited by the NOS inhibitor. GLP-1 augmented eNOS phosphorylation in HCAECs, with the effect completely disappearing after exposure to the protein kinase A (PKA) inhibitor H89. These data suggest that anagliptin treatment enhances insulin-induced capillary recruitment and interstitial insulin concentrations, resulting in improved skeletal muscle glucose uptake by directly acting on the endothelial cells via NO- and GLP-1-dependent mechanisms in vivo.Anagliptin may be a promising agent to ameliorate skeletal muscle insulin resistance in obese patients with type 2 diabetes." @default.
• W2512856880 created "2016-09-16" @default.
• W2512856880 creator A5001757567 @default.
• W2512856880 creator A5008659249 @default.
• W2512856880 creator A5009377592 @default.
• W2512856880 creator A5023747492 @default.
• W2512856880 creator A5032606840 @default.
• W2512856880 creator A5032987460 @default.
• W2512856880 creator A5037873586 @default.
• W2512856880 creator A5038013237 @default.
• W2512856880 creator A5040548657 @default.
• W2512856880 creator A5049698622 @default.
• W2512856880 creator A5057378675 @default.
• W2512856880 creator A5060858053 @default.
• W2512856880 date "2016-08-15" @default.
• W2512856880 modified "2023-10-12" @default.
• W2512856880 title "Anagliptin increases insulin-induced skeletal muscle glucose uptake via an NO-dependent mechanism in mice" @default.
• W2512856880 cites W1949701648 @default.
• W2512856880 cites W1969750989 @default.
• W2512856880 cites W1978030502 @default.
• W2512856880 cites W1992116679 @default.
• W2512856880 cites W1995209325 @default.
• W2512856880 cites W2010102296 @default.
• W2512856880 cites W2014520461 @default.
• W2512856880 cites W2015017251 @default.
• W2512856880 cites W2018717417 @default.
• W2512856880 cites W2022921728 @default.
• W2512856880 cites W2028849170 @default.
• W2512856880 cites W2032089792 @default.
• W2512856880 cites W2033125833 @default.
• W2512856880 cites W2033746638 @default.
• W2512856880 cites W2038230197 @default.
• W2512856880 cites W2054185381 @default.
• W2512856880 cites W2058885439 @default.
• W2512856880 cites W2059909265 @default.
• W2512856880 cites W2064624100 @default.
• W2512856880 cites W2065526508 @default.
• W2512856880 cites W2068291692 @default.
• W2512856880 cites W2071835038 @default.
• W2512856880 cites W2079681415 @default.
• W2512856880 cites W2098083442 @default.
• W2512856880 cites W2098459806 @default.
• W2512856880 cites W2104763836 @default.
• W2512856880 cites W2110576471 @default.
• W2512856880 cites W2118913197 @default.
• W2512856880 cites W2129639460 @default.
• W2512856880 cites W2130375560 @default.
• W2512856880 cites W2141757949 @default.
• W2512856880 cites W2147091345 @default.
• W2512856880 cites W2148182710 @default.
• W2512856880 cites W2153361294 @default.
• W2512856880 cites W2170606300 @default.
• W2512856880 cites W4234825176 @default.
• W2512856880 cites W68697002 @default.
• W2512856880 cites W941973657 @default.
• W2512856880 doi "https://doi.org/10.1007/s00125-016-4071-8" @default.
• W2512856880 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27525648" @default.
• W2512856880 hasPublicationYear "2016" @default.
• W2512856880 type Work @default.
• W2512856880 sameAs 2512856880 @default.
• W2512856880 citedByCount "15" @default.
• W2512856880 countsByYear W25128568802017 @default.
• W2512856880 countsByYear W25128568802018 @default.
• W2512856880 countsByYear W25128568802019 @default.
• W2512856880 countsByYear W25128568802020 @default.
• W2512856880 countsByYear W25128568802021 @default.
• W2512856880 countsByYear W25128568802022 @default.
• W2512856880 countsByYear W25128568802023 @default.
• W2512856880 crossrefType "journal-article" @default.
• W2512856880 hasAuthorship W2512856880A5001757567 @default.
• W2512856880 hasAuthorship W2512856880A5008659249 @default.
• W2512856880 hasAuthorship W2512856880A5009377592 @default.
• W2512856880 hasAuthorship W2512856880A5023747492 @default.
• W2512856880 hasAuthorship W2512856880A5032606840 @default.
• W2512856880 hasAuthorship W2512856880A5032987460 @default.
• W2512856880 hasAuthorship W2512856880A5037873586 @default.
• W2512856880 hasAuthorship W2512856880A5038013237 @default.
• W2512856880 hasAuthorship W2512856880A5040548657 @default.
• W2512856880 hasAuthorship W2512856880A5049698622 @default.
• W2512856880 hasAuthorship W2512856880A5057378675 @default.
• W2512856880 hasAuthorship W2512856880A5060858053 @default.
• W2512856880 hasBestOaLocation W25128568801 @default.
• W2512856880 hasConcept C112446052 @default.
• W2512856880 hasConcept C126322002 @default.
• W2512856880 hasConcept C134018914 @default.
• W2512856880 hasConcept C185592680 @default.
• W2512856880 hasConcept C2777180221 @default.
• W2512856880 hasConcept C2777391703 @default.
• W2512856880 hasConcept C2777622882 @default.
• W2512856880 hasConcept C2777866211 @default.
• W2512856880 hasConcept C2778326061 @default.
• W2512856880 hasConcept C2778763485 @default.
• W2512856880 hasConcept C2778881409 @default.
• W2512856880 hasConcept C2779306644 @default.
• W2512856880 hasConcept C2779959927 @default.
• W2512856880 hasConcept C519581460 @default.
• W2512856880 hasConcept C555293320 @default.
• W2512856880 hasConcept C71924100 @default.

• next